It was discovered that antigen-binding molecules comprising (i) a domain that binds to a molecule expressed on the surface of cells having immune response-suppressing functions, and (ii) a T cell receptor complex-binding domain exhibit more superior antitumor effects than conventional antigen-binding molecules by crosslinking T cells with cells having immune response-suppressing functions, and damaging the cells having immune response-suppressing functions.